Sosei is a Japanese listed, international biopharmaceutical company, with near term sustainable revenue from products out-licensed from a portfolio centred on inflammation and pain.
From its inception Sosei has had global aspirations and operated internationally linking Japan with the west.
Operating on a cross-border basis is a challenge which Sosei has embraced. It is an integral part of its evolving business model, leading ultimately towards making a significant contribution to improving the quality of life and health of people around the world.
As the pharmaceutical industry environment changes Sosei seeks to adapt without losing its focus on the successful reprofiling, development and commercialisation of its compounds and its aim to become a top-tier biopharmaceutical company which capitalises upon its unique Anglo-Japanese operations.
